Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Any news on why it was halted?
Take a look at the Biotechnology Index, MG516.
Did he respond?
oil have you sent Ike the link to this video?
GOIG...$.0028-Closed above the 20 dma(.00277). Resistance seems to be @.0035
Holy doodies. What happened? QSGIQ not looking too good lately.
Over half the volume today came in the last 21 minutes and it was all buys. Going to like Monday. Does somebody know or expect something Monday morning?
Big buys at the end of day. More buys than sells.
INHX..$4.38 hod...Wowza.
Lovaza side effects.
http://www.ehow.com/about_5377222_lovaza-side-effects.html
INHX..$3.55...Canaccord Genuity raises Inhibitex Inc price target to $7 from $5; reiterates buy rating.
AVNR...Don't like the sound of that. Took my profit.
NLTX..$.819....up .21
FDA fast-tracks Nile Therapeutics drug
Silicon Valley / San Jose Business Journal
Date: Thursday, March 31, 2011, 5:32am PDT
Nile Therapeutics Inc. said Thursday its cenderitide therapy was granted Fast Track designation by the U.S. Food and Drug Administration.
San Mateo-based Nile (NASDAQ:NLTX) said cenderitide's goal is to reduce "cardiovascular mortality and cardiovascular re-hospitalization in the post-acute period in patients with acute decompensated heart failure."
Nile plans to develop cenderitide as an outpatient therapy that will be used on patients for up to 90 days after discharge from the hospital.
Fast Track is a designation that the FDA reserves for products that demonstrate the potential to address unmet medical needs for serious or life-threatening conditions
INHX..$3.22....Inhibitex Reports Positive Safety and Antiviral Data from Its Phase 1b Study of HCV Nucleotide Inhibitor INX-189
-Potent Dose-Dependent Antiviral Activity Demonstrated with Once-Daily Administration-
-Viral Load Declines in Combination with Ribavirin Confirm Antiviral Synergy-
Press Release Source: Inhibitex, Inc. On Thursday March 31, 2011, 5:00 am EDT
ATLANTA--(BUSINESS WIRE)-- Inhibitex, Inc. (Nasdaq:INHX - News) today reported positive top-line safety and antiviral data from its multiple ascending dose Phase 1b clinical trial of INX-189, an oral nucleotide polymerase inhibitor being developed to treat chronic infections caused by hepatitis C virus (HCV).
The trial was a double-blind, placebo-controlled, dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of INX-189, administered orally once-daily for seven days, in HCV genotype 1 treatment naïve patients. A total of 70 subjects were randomized into the trial among seven different dosing cohorts, including five monotherapy treatment arms and two arms of adjunctive treatment with ribavirin (RBV). Each treatment cohort in the study was comprised of 10 patients, eight of whom received INX-189 and two that received placebo.
INX-189, dosed once-daily at 9, 25, 50 and 100 mg for seven days, demonstrated potent and dose-dependent antiviral activity with median HCV RNA reductions from baseline of -0.64, -1.00, -1.47, and -2.53 log10 IU/mL, respectively. INX-189, dosed once-daily at 50 mg for one day, followed by 9 mg for six days, achieved a median HCV RNA reduction from baseline of -0.50 log10 IU/mL. The median HCV RNA decline from baseline observed in patients that received placebo was -0.20 log10 IU/mL. INX-189, dosed once-daily in combination with RBV for seven days at 9 mg and 25 mg, resulted in median HCV RNA reductions from baseline of -0.75 and -1.56 log10 IU/mL, respectively. The median HCV RNA decline from baseline observed in patients that received placebo and RBV was 0.04 log10 IU/mL.
Cohort
(INX-189 QD) Median HCV log10 IU/mL RNA
Viral Load Decline after 3 doses Median HCV log10 IU/mL RNA
Viral Load Decline after 7 doses Range Day 7
HCV log10 IU/mL RNA
Placebo
(n=10) 0.25 -0.20 0.60 to -0.30
9 mg
(n=7) -0.29 -0.64 -0.19 to -1.06
25 mg
(n=8) -0.85 -1.00 -0.56 to -1.58
50 mg
(n=8) -1.34 -1.47 -1.17 to -2.30
100 mg
(n=8) -1.46 -2.53 -1.35 to -2.78
50 mg x 1 day
9 mg x 6 days
(n=7) -0.46 -0.50 0.11 to -0.88
RBV with
Placebo
(n=4) -0.13 0.04 1.47 to -0.61
9 mg
with RBV
(n=7) -0.45 -0.75 -0.35 to -0.93
25 mg
with RBV
(n=8) -1.35 -1.56 -0.77 to -2.68
In addition to these median reductions in viral load, clinically meaningful decreases in alanine transaminase (ALT) levels were observed for patients receiving INX-189 at all dose levels, and no patients experienced viral breakthrough.
Additional data available from the Phase 1b study indicate that INX-189 was generally well tolerated. There was one serious adverse event reported in a subject treated with RBV and placebo (atrial fibrillation in a subject with a previous history). All other reported adverse events were mild or moderate, with the most common adverse event in INX-189 treated subjects being headache. There were no discontinuations of treatment due to adverse events and there were no adverse events related to changes in clinical laboratory evaluations or ECGs.
“Nucleotide polymerase inhibitors are likely to be a key component of combination direct antiviral therapy,” stated Dr. Eric Lawitz, President and Medical Director at Alamo Medical Research, San Antonio, Texas and a principal investigator of the Phase 1b study. “Further, the antiviral activity observed at the low INX-189 doses evaluated is promising, provides proof of concept, and provides the foundation for future studies.”
“The potent antiviral activity in monotherapy and the synergistic activity observed in combination with RBV support our belief that INX-189 has the potential to play a pivotal role in future HCV combination therapy,” commented Joseph M. Patti, Ph.D., Inhibitex’s CSO and Senior Vice-President of Research. “We believe these data, taken together with the successful completion of our 13-week GLP toxicology studies, support advancing INX-189 into Phase 2 clinical trials later this year.”
About HCV and INX-189
Hepatitis C is a disease of the liver caused by HCV. It is estimated that over 4 million Americans and 170 million individuals worldwide are infected with HCV, the majority of which represent chronic infections that can cause liver disease, cirrhosis and cancer, and is the leading cause of liver transplants in the United States.
Inhibitex is developing a series of proprietary nucleotide inhibitors that target the RNA-dependent RNA polymerase (NS5b) of HCV. INX-189 is a protide of a 2’-C-methyl guanosine analogue. The Company believes that preclinical and clinical studies of INX-189 completed to-date support its potential as a potent, once-daily, low dose oral therapy amenable to combination with other antivirals for the treatment of patients with all known genotypes of HCV.
http://finance.yahoo.com/news/Inhibitex-Reports-Positive-bw-1052714802.html?x=0&.v=1
If you are on the CSKH board just click "Trades" at the top of the page.
More buys than sells today. About 5 to 1
agreed.
QSGIQ....Oops there she goes again.LOL
Did you ever go by the handle StockMama? You post a lot like a long poster on the old THRR board.
The reorganized Debtor anticipates that it will likely emerge from Chapter 11 following the May 26, 2011 status conference with the United
States Bankruptcy Court Southern District of Florida, West Palm Beach Division. Although Debtors’ anticipate that all conditions that the
Debtors must satisfy before the Effective Date, other than the passage of time, will have been satisfied," the Debtors can make no assurances as
to when, 'or ultimately if', the Plan will become effective."
There are never any guarantees!
EXCUSE ME! I asked a question. Nobody seems to have the answer.
So how much are QSGIQ liabilities and what are their assets worth?
Maybe in your world they're the same.LOL
I thought this wasn't a penny stock!
Mean price target for AMRN.....$10.34 so I'd have to say it is not figured into the price.
http://finance.yahoo.com/q/ao?s=AMRN+Analyst+Opinion so I'd have
Excellent dd on ECTE. Thanks for sharing. I will buy more ECTE next week.
INHX..$3.14, popping above $3.10 resistance on strong volume, 842.1k.
I'm in ECTE. Nice chart, went down and bounced off the 50 dma nicely.
Yeah, it would be nice to see the flippers gone too!
Being in this stock may make me a mental patient, but I have patience.
I agree. Good video you shared. Thanks.
So you're saying it's because of penny traders that the pps fell. How ridiculous! How about pumpers selling into their pump?
Did you mean wasting time? I think I'll stay for a while!
Please, if it quacks, has a bill and feathers it's a duck. I know what I'm seeing here.
I know, typical P&D.
This board was very busy yesterday, all about the news and how this would fly today. Now the peeps posting abot this yesterday are sort of quiet today and no big run up in price yet. I wonder why..........
I'm right there KABOOMING with you:)
AMRN....macd finally crossed up.
No KABOOM yet. what's up with that??
OMER(Omeros Corporation)..$6.76
Omeros' Ophthalmology Product OMS302 Achieves Co-Primary Endpoints in Phase 2b Clinical Study
Related Quotes
Symbol Price Change
OMER 6.85 +0.80
Press Release Source: Omeros Corporation On Wednesday March 23, 2011, 7:00 am EDT
SEATTLE, March 23, 2011 /PRNewswire/ -- Omeros Corporation (Nasdaq:OMER - News), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today reported positive data from a Phase 2b clinical trial evaluating OMS302 in patients undergoing cataract surgery. OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros' proprietary PharmacoSurgery™ product in development to maintain intra-operative mydriasis (pupil dilation) and reduce postoperative pain and irritation resulting from cataract and other lens replacement surgery.
In this 221-patient Phase 2b clinical study, subjects treated with OMS302 demonstrated statistically significant (p<0.0001) and clinically meaningful maintenance of mydriasis throughout the cataract procedure. If mydriasis is not maintained throughout the procedure, the risk of injuring structures within the eye increases and the required operating time is often prolonged. Of equal clinical relevance, OMS302 also significantly decreased (p=0.0418) pain in the early postoperative period and reduced the frequency of complaints of moderate and severe pain (2.5 times more complaints in the vehicle-treated patients). The drug product was safe and well tolerated in this study.
"These data are compelling and could represent a major advance for lens replacement procedures, including cataract surgery and refractive lens exchange. OMS302 has the ability to facilitate the ease of the procedure while improving patient outcomes and safety," stated Alan S. Crandall, M.D., director of glaucoma and cataract, senior vice chairman of ophthalmology and visual sciences at the Moran Eye Center, University of Utah, and the immediate past president of the American Society of Cataract and Refractive Surgery.
"Maintenance of mydriasis is critical to performing lens exchange safely and proficiently. In addition to the significant mydriatic benefit of OMS302 seen in this study, the reduction in pain reported by OMS302-treated patients is clinically important," stated Mark I. Rosenblatt, M.D., Ph.D., associate professor of ophthalmology, Weill Cornell Medical College. "Because OMS302 is administered through the irrigation solution currently used during lens exchange, the drug product fits readily into the workflow of the operating room and does not require a change in the surgeon's routine procedure."
"We are pleased that OMS302 demonstrated statistically significant and clinically relevant benefits in this full-factorial Phase 2b study," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "Each component of the drug product showed clear efficacy. Given the strength and consistency of these clinical data, we have begun preparations for a pivotal Phase 3 program."
http://finance.yahoo.com/news/Omeros-Ophthalmology-Product-prnews-3270768282.html?x=0&.v=1